GlassScriptPhysician profile
Chhavi Gupta
NPI 1003052945
$5,219.11
in general payments reported to CMS, 2019-2025
26 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $242 · 2021: $342 · 2022: $646 · 2023: $1,064 · 2024: $1,018 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488 · Education: $27.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,487.98 |
| Education | $27.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $718.62 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $568.43 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Travere Therapeutics, INC. | $478.44 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $467.36 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.91 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $341.03 | 2020-2024 | Acthar |
| Horizon Therapeutics Plc | $292.65 | 2019-2023 | Krystexxa |
| Amgen INC. | $252.99 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Novartis Pharmaceuticals Corporation | $218.49 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $185.04 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $156.28 | 2022-2023 | Lupkynis |
| Lilly USA, LLC | $141.96 | 2023-2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $134.11 | 2022-2025 | Rayaldee |
| Portola Pharmaceuticals, LLC | $124.90 | 2019 | |
| Abbvie INC. | $121.12 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $121.12 | 2025 | Vyvgart |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.99 | 2019 | |
| Vifor Pharma, INC. | $85.02 | 2019-2021 | |
| Ardelyx, INC. | $81.65 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $56.41 | 2024-2025 | Benlysta, Jesduvroq |
| Azurity Pharmaceuticals, INC. | $33.52 | 2025 | Edarbi |
| Cormedix INC. | $25.45 | 2024 | Defencath |
| Shield Therapeutics INC | $24.69 | 2023 | Accrufer |
| Alexion Pharmaceuticals, INC. | $23.74 | 2022 | |
| Akebia Therapeutics INC | $17.23 | 2020 | |
| Shire North American Group INC | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chhavi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.